Healthcare & Medical Investment Corporation
Notice Regarding Bylaw Changes and Director Appointments
This investment corporation submitted for the 7th general meeting of investors a plan to change the management structure, including the appointment of one executive officer, one replacement executive officer, and two supervisory officers. Partial bylaw amendments are also to be approved. The meeting is scheduled for October 29, 2026. Technical changes to remuneration calculation rules for the asset management company are also announced concurrently.
Key Figures
- Appointment of one executive officer
- Appointment of one replacement executive officer
- Appointment of two supervising officers
AI要約
Overview of Bylaw Changes
The investment corporation plans to revise bylaws to respond to the establishment of the Asset Management Association, presenting amendments 1–5 including updating current clauses, new electronic provision measures, and handling of usufruct assets that are excluded from asset management fees. In particular, revisions to Articles 9–21 clarify conditions for officers such as convocation and chairing, and strengthen the structure by setting an upper limit on the number of executive officers.
Details of Director Appointments and Schedule
New candidate for one executive officer, one candidate for replacement executive officer, and two candidates for supervising officers have been submitted. Executive officer candidate is Yuji Fujise; replacement executive officer candidate is Akashi Muramura; supervising officer candidates are Kaori Sato and Nomu Nakano. Term of office will commence on November 1, 2026 in accordance with the current bylaws. The general meeting is scheduled for October 29, 2026.
Healthcare & Medical Investment Corporation
Company overview · Stock price · Financial data · All IR
